That’s a very good point — it really does look like the MHRA is using DCVax-L not just as a single product review, but as a pilot case to refine the regulatory framework for digitally managed, autologous cell therapies.
The recent CGT Catapult–Autolomous white paper (Oct 2025) is a perfect example of this “system-building” approach. Although it focused on a CAR-T process rather than a dendritic cell therapy, it validated — in a real MHRA-licensed environment — that fully digital GMP manufacturing via the autoloMATE™ platform can ensure full MHRA/EMA/FDA-compliant data integrity, enable end-to-end traceability, cut documentation-review time by 65%, and eliminate paper entirely.
Since DCVax-L is manufactured using this same digital infrastructure at Sawston, it’s reasonable to think the MHRA wanted this government-backed validation in place before concluding its assessment — not because there are regulatory obstacles, but because DCVax-L serves as the first real-world test case for embedding these digital manufacturing standards into the UK’s regulatory framework. In that sense, murcidencel/DCVax-L isn’t just a product under review — it’s the prototype guiding how future personalised cell and gene therapies will be regulated. IMO. https://ct.catapult.org.uk/news/cgt-catapult-and-autolomous-showcase-benefits-of-digital-technologies-in-advanced-therapy-manufacturing
LOL, new excuses! From approval in March-April to now trying to convince yourself that delays are due to MHRA shaping new regulatory framework because of DCVAX-L.
If MHRA was that convinced, DCVAX-L would have been approved a while back. Besides, MHRA wouldn’t be holding up approval for a highly unmet disease until the official guidelines and frameworks catch up. MHRA already confirmed that this wasn’t necessary if the data was really convincing.
Market Data 
Markets 
AI
